$2.1mn Awarded For Chembio Diagnostics to Develop Multiplex Assay for Febrile Illnesses

Microsoft Co-Founder Paul G. Allen has awarded this grant for the development of a highly-sensitive and affordable rapid point-of-care multiplex assay.

Microsoft Co-Founder Paul G. Allen has awarded $2.1 million dollar grant for Chembio Diagnostics to develop a POC test to identify multiple life-threatening febrile illnesses.

Chembio will use its patented Dual Path Platform (DPP®) technology to develop a POC multiplex assay to simultaneously detect Malaria, Dengue, Ebola, Lassa, Marburg, and Chikungunya.

$6 Million Grant Awarded By Bill Gates To Develop a Alternative HIV/AIDS Vaccine
Scientists at The Scripps Research Institute (TSRI) received the grant to make the already shown effective HIV/AIDS vaccine in animals for humans.

Misdiagnosis of febrile illnesses result in high morbidity and mortality across the world. Misdiagnosis may be due to the fact that these diseases have similar symptoms that are difficult to identify.

Through this grant, it is the goal of the Paul G. Allen Ebola Program to develop a simple, cost-effective, point-of-care diagnostic capable of testing for multiple diseases simultaneously, to ensure that patients receive the appropriate treatment, and healthcare workers offer optimal care to communities through the accurate diagnosis of febrile illness.

The assay will be designed with a quality control test band and seven tests bands with specific antibodies to detect different pathogens, including multiple serotypes of the same pathogen: Malaria PAN-PLDH antigen (Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale), Malaria Falciparum HRP2 antigen, Ebola Virus PAN (Zaire, Sudan, Bundibugyo Virus), Marburg Virus, Lassa Virus, Dengue Virus (Dengue 1, Dengue 2, Dengue 3, Dengue 4) and Chikungunya Virus.

Alzheimer�s Association of San Diego Receives $1 Million to Train First-Responders
First-Responders are people like police officers who respond and care for the mentally-challenged first in a community and the association plans to train them.

Javan Esfandiari, Chief Science and Technology Officer (CSTO) of Chembio commented, “We are honored and excited that the Paul G. Allen Ebola Program has selected Chembio’s patented DPP® technology for the development of this highly-sensitive, specific and affordable rapid point-of-care multiplex assay for febrile illness. A small, cost-effective, battery-operated digital reader will be used to read the test results and report them electronically. We believe the DPP® Fever Panel Assay and reader will become important tools in the battle against emerging disease worldwide.”

John Sperzel, Chembio's Chief Executive Officer, commented, "It is a corporate priority to be first-to-market with a DPP® Fever Panel Assay to test for multiple fever diseases concurrently, with a single fingerstick blood sample. Today’s partnership brings this goal within reach, and we are delighted to partner with the Paul G. Allen Ebola Program in this important endeavor.”

$20,000 Grant for William Carey University to Assist Adults With Intellectual Disabilities
A music therapy program and Quality of Life Project will be developed to increase acquisition of skill-building and promote daily activities in these students.

“Chembio affirms its commitment to the development of new and much-needed POC tests for life threatening fever diseases. Under this latest grant, we intend to develop new assays for Marburg Virus, Lassa Virus, and Chikungunya Virus, which will be combined with our recently developed assays for Malaria, Dengue Fever and Ebola Virus to complete the DPP® Fever Panel Assay development in the next 12 months," he said.

Source-Medindia

Mother and Child Health� Research Awarded Grants For New Innovations
The awards were given by K. Vijay Raghavan, secretary in the department of biotechnology under the central government.